The Anti-Obesity Drugs Market is booming, with a value of $5.75 billion in 2024 and projected to reach $35.52 billion by 2032, showing a CAGR of 25.59%. The U.S. is leading this growth, with a market size expected to reach $10.28 billion by 2032. Major companies in this market include Novo Nordisk and Eli Lilly.

Prescription drugs dominate the global anti-obesity drugs market, holding 86% of the market share in 2024. Online and retail pharmacies lead in distribution channels, with the online segment accounting for over 64% of the market value. North America is the dominant market due to high obesity rates and well-developed healthcare systems.

In January 2025, the Biden administration introduced measures to tackle obesity by promoting access to weight-loss treatments. U.S. pharmaceutical spending surged in April 2024, driven by demand for obesity medications. The report also covers obesity incidence, drug prescription trends, healthcare spending, regulatory landscape, and public awareness.

The Anti-Obesity Drugs Market report provides in-depth analysis, including market size, growth projections, regional coverage, and key segments. Related reports on diabetes devices, metabolic disorder therapeutics, weight loss devices, weight loss drugs, and bariatric surgery are also available. SNS Insider aims to provide clients with accurate market data to make informed decisions.

Read more at GlobeNewswire: Anti-Obesity Drugs Market Size to Reach $35.52 Billion by